Leslie L. Citrome, MD, MPH

With five adjunctive atypical antipsychotics now approved for MDD, tolerability differences do most of the deciding. The panel matches specific side-effect profiles to individual patients and raises when tapering should begin.

Modest efficacy gains from switching push many clinicians toward augmentation instead. The panel weighs guideline thresholds, side-effect-driven medication matching, and the polypharmacy risks that complicate adding a second agent.

Generic antidepressant switching has little supporting evidence, and Erin Crown explains why she often chooses early augmentation instead, guided by each patient's risk factors.

Deciding whether to switch medications or build on a partial response shapes every subsequent treatment choice. Dr. Citrome outlines the criteria that separate a true nonresponse from a foundation worth augmenting.

In-person visits let Erin Crown read incongruence between what a patient says and how they present, and one encounter years ago showed her exactly why that matters.

A vague sense of 'blah' is often the last symptom to lift. Dr. Harding and Dr. Citrome examine why anhedonia and disrupted sleep persist longest, and how tracking them closely reveals early warning signs.

A patient's improving score does not always translate into a patient who feels better, and Erin Crown explains how anhedonia and cognitive symptoms account for the gap.

More than half of patients treated for depression don't believe full remission is achievable. The panel explores what success should mean to the patient in front of you, and why patients rarely admit they've stopped taking a medication.

Standardized questionnaires matter, but Erin Crown leans on detailed conversation about a patient's daily routines to catch functional changes that no scale fully captures.

Standardized rating scales define response and remission in clinical trials, but Erin Crown argues real recovery means returning fully to the life a patient had before depression began.

A PHQ-9 score can mislead as easily as it clarifies. The panel unpacks the gap between rating-scale remission and how patients actually experience recovery, using real cases where appearances and scores diverged sharply.

Precision medicine looks different in psychiatry than in oncology. The panel discusses why personalizing MDD care starts with a complete patient history, and how clinical experience, evidence, and patient goals combine to guide treatment.

Many symptoms that most impair patients with major depressive disorder go unspoken until treatment starts working, making early recognition and patient-defined goals central to effective care.

Depression's cardinal symptoms are often invisible to the patient reporting them. Dr. Harding and Dr. Citrome examine why diagnosis, not treatment, remains psychiatry's hardest task, and how family observation and screening for bipolar depression change the diagnostic path.

A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.

ASCP panel offers deprescribing guidance to curb psychiatric overprescribing, simplify polypharmacy, and improve outcomes with tapering and

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

ASCP awardee Leslie Citrome explains why effect size, NNT, and NNH beat P-values, helping clinicians choose treatments tailored to each patient.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

What makes this treatment option unique?

Drs Paul Doghramji and Leslie Citrome share approaches to communicate with patients and increase awareness of insomnia disorder

Leslie Citrome, MD, MPH, comments on long-term data for daridorexant, suvorexant, and lemborexant.

Experts discuss daridorexant efficacy and safety data, and dosing considerations and what to communicate with patients when using daridorexant for insomnia.

Drs Paul Doghramji and Leslie Citrome provide an overview of dual orexin receptor antagonists (DORAs), suvorexant, lemborexant, and daridorexant, in treatment of insomnia disorder.

Drs Paul Doghramji and Leslie Citrome discuss the sleep and wakefulness signals and pathways that contribute to insomnia.

Drs Paul Doghramji and Leslie Citrome review the use of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) to assess treatment efficacy.

Experts discuss treatment for patients experiencing insomnia in conjunction with other health conditions.

Drs Paul Doghramji and Leslie Citrome review prescription drugs and over-the-counter remedies for treating insomnia.

Experts highlight cognitive behavioral therapy for insomnia (CBTI) and sleep hygiene as nonpharmacological approaches to the treatment of insomnia.

Drs Paul Doghramji and Leslie Citrome discuss daytime sleepiness and other symptoms of insomnia and their impact on quality of life.